Adrenal crisis Market Outlook 2034 - Competitive Landscape, Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

DelveInsight's "Adrenal crisis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Adrenal crisis, historical and forecasted epidemiology as well as the Adrenal crisis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Adrenal crisis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Adrenal crisis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Adrenal crisis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Adrenal crisis market.

To Know in detail about the Adrenal crisis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Adrenal crisis Market Forecast
https://www.delveinsight.com/report-store/adrenal-crisis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Adrenal crisis Market Report:
• The Adrenal crisis market size was valued approximately USD 11.5 Million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In 7MM nations, there were 130,175 prevalent instances of adrenal crisis in 2021
• Acute life-threatening conditions like adrenal crisis, also known as acute adrenal insufficiency and Addisonian crisis, continue to be a major cause of death in people with adrenal insufficiency
• Elshimy et al. (2021) describe an increase in the reported prevalence of adrenal insufficiency in Europe over time
• According to Miller et al. (2020), adrenal insufficiency (AI), which is characterised by an annual estimated incidence of adrenal crisis of 5-10 episodes per 100 patient-years, is a substantial source of morbidity and mortality in children.
• Key Adrenal crisis Companies: Takeda Pharmaceutical, Sandoz International GmbH, Pfizer Inc, Bristol-Myers Squibb, Merck KGaA, Antares Pharma, Mallinckrodt Pharmaceutical, Mylan Pharmaceutical, AG eTon Pharmaceuticals, and others
• Key Adrenal crisis Therapies: ATRS-1902, SOLU-CORTEF and others
• The Adrenal crisis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Adrenal crisis pipeline products will significantly revolutionize the Adrenal crisis market dynamics.
• In May 2025, Eton Pharmaceuticals, Inc ("Eton" or "the Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the U.S. Food and Drug Administration (FDA) approval of a New Drug Application (NDA) for KHINDIVITM (hydrocortisone) Oral Solution as a replacement therapy in pediatric patients five years of age and older with adrenocortical insufficiency.

Adrenal crisis Overview
An adrenal crisis, also known as an Addisonian crisis, is a life-threatening condition that occurs when there is a severe deficiency of cortisol, a hormone produced by the adrenal glands. This deficiency can result from untreated Addison's disease, sudden discontinuation of glucocorticoid medications, or situations that increase the body's need for cortisol, such as stress, infection, or surgery.
Symptoms of adrenal crisis include severe fatigue, weakness, confusion, low blood pressure, severe abdominal pain, vomiting, diarrhea, dehydration, and shock. These symptoms can rapidly progress and become fatal if not promptly treated.

Diagnosis of adrenal crisis is based on clinical presentation and blood tests showing low cortisol levels, along with electrolyte imbalances such as hyponatremia (low sodium) and hyperkalemia (high potassium).
Immediate treatment is critical and involves intravenous administration of hydrocortisone, saline fluids to correct dehydration and electrolyte imbalances, and glucose if hypoglycemia is present. Identifying and treating the underlying cause of the crisis is also essential.
Preventive measures for those at risk include regular monitoring, adjusting medication dosages during periods of stress or illness, and carrying emergency medical information indicating their condition. Awareness and prompt intervention can significantly improve outcomes and prevent potentially fatal complications associated with adrenal crisis.

Get a Free sample for the Adrenal crisis Market Report to know more in detail about the epidemiology and treatment algorithm @ https://www.delveinsight.com/report-store/adrenal-crisis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Adrenal crisis Epidemiology
Between 2019 and 2020, adrenal crisis was estimated to occur at a rate of around 5.2 to 8.3 cases per 100 patient-years, with a postal survey of over 1,000 individuals with primary adrenal insufficiency (PAI) indicating an annual frequency of about 8%. Overall, patients with adrenal insufficiency experience adrenal crises in roughly 6-8% of cases each year. An analysis of more than 400 individuals with adrenal insufficiency showed a similar prevalence of approximately 8 adrenal crises per 100 patient-years. Within the broader population, prevalence rates were about 38% for primary adrenal insufficiency, 57% for secondary adrenal insufficiency, and 6% for congenital adrenal hyperplasia (CAH). In terms of treatment, conventional hydrocortisone remains the most widely used therapy, followed by prednisolone, while dexamethasone is used least often. The analysis also revealed that females were more commonly affected than males across all adrenal insufficiency groups.

Adrenal crisis Epidemiology Segmentation:
The Adrenal crisis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Adrenal crisis
• Prevalent Cases of Adrenal crisis by severity
• Gender-specific Prevalence of Adrenal crisis
• Diagnosed Cases of Episodic and Chronic Adrenal crisis

Download the report to understand which factors are driving Adrenal crisis epidemiology trends @ Adrenal Crisis Market Dynamics
https://www.delveinsight.com/report-store/adrenal-crisis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Adrenal crisis Market Outlook
The adrenal crisis market is influenced by several dynamics, with increasing awareness and diagnosis of adrenal insufficiency being key drivers. Rising incidences of autoimmune diseases, such as Addison's disease, and growing recognition of adrenal crisis as a life-threatening condition are driving the demand for timely interventions. Moreover, advancements in treatment options, including corticosteroids and hormone replacement therapies, are positively impacting market growth. However, barriers such as the high cost of treatment, limited access to healthcare in developing regions, and the complexity of diagnosing adrenal crisis early hinder market expansion. Additionally, the market faces challenges in terms of patient adherence to long-term treatment regimens, as well as the side effects associated with corticosteroid use. Despite these challenges, ongoing research into novel therapeutic approaches and improvements in patient education present opportunities for growth in the adrenal crisis market.

Adrenal crisis Market Dynamics and Trends
Adrenal crisis Market Drivers
1. Rising Prevalence of Adrenal Insufficiency / Adrenal Disorders
Increased recognition of adrenal insufficiency (due to autoimmune diseases, infections, use of corticosteroids, etc.) is raising the at-risk population.
This expanded patient base drives demand for therapies and crisis-management solutions.
2. Greater Awareness & Improved Diagnostics
More education among physicians and patients is leading to earlier detection of adrenal insufficiency and adrenal crisis risk.
Advances in diagnostic tools (hormonal assays, stimulation tests, point-of-care testing) improve disease identification rates and monitoring.
3. Innovative Therapeutics & Delivery Technologies
There is a push in R&D for next-generation corticosteroid formulations, auto-injectors, long-acting implants, or better drug delivery modes for crisis settings.
These innovations enhance patient convenience, may reduce hospital burden, and address unmet needs in acute care.
4. Regulatory Incentives, Fast-Track Designations & Rare Disease Support
Because adrenal crisis is often considered within the spectrum of rare endocrine emergencies, regulators may offer pathway accelerations or orphan-drug incentives, which encourage investment.
Fast-track status, priority reviews, and regulatory support can reduce time to market and lower risk for developers.
5. Expansion in Emerging Geographies & Healthcare Access
As healthcare infrastructure, insurance coverage, and drug distribution improve in Asia, Latin America, and other developing markets, the addressable market widens.
Growth of telemedicine, e-pharmacies, and digital health platforms helps reach remote or underserved patients.

Adrenal crisis Market Barriers
1. Limited Approved Treatment Options & Clinical Evidence
There are relatively few therapies specifically approved for adrenal crisis beyond standard corticosteroid protocols.
Lack of robust comparative clinical studies, especially in acute crisis settings, constrains adoption of novel therapies.
2. High Costs of Advanced Therapies & Formulations
Innovative delivery systems, long-acting formulations, and auto-injectors are costlier to develop and manufacture, potentially limiting affordability or reimbursement.
In markets with strict price controls (or low willingness to pay), premium-priced adrenal crisis therapies face adoption challenges.
3. Regulatory & Approval Hurdles
Ensuring safety, efficacy, and manufacturing standards in emergency-use settings is demanding. Novel formulations often face rigorous scrutiny.
Differences in regulatory frameworks across countries slow global rollout.
4. Patient & Physician Adoption / Awareness Gaps
Even though awareness is improving, misdiagnosis or delayed diagnosis of adrenal crisis remains common, reducing effective utilization of prophylactic or early-intervention therapies.
Clinicians in many locations may still follow legacy treatment protocols, hindering uptake of new solutions.
5. Logistics, Supply Chain, & Emergency Access Issues
In many regions, ensuring emergency stock, cold-chain (if required), and rapid availability in acute settings is a challenge.
Rural or low-resource areas may struggle to access injectable therapies or advanced delivery systems.
6. Adherence & Real-World Use Constraints
In emergencies, self-administration may be difficult (pain, glucocorticoid stress, confusion). Patients may underdose or delay treatment.
Monitoring, dose adjustments, and patient training impose ongoing costs.

Adrenal crisis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Adrenal crisis market or expected to get launched during the study period. The analysis covers Adrenal crisis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Adrenal crisis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Adrenal crisis Therapies and Key Companies
• ATRS-1902: Antares Pharmaceuticals
One significant asset in the pipeline is ATRS-1902, originally developed by Antares Pharma and advanced to Phase III clinical development. Intended for administration during adrenal crisis situations, the treatment was granted FDA Fast Track status in January 2022. In the same month, the company also released encouraging Phase I data for ATRS-1902, which targeted adrenal crisis rescue. The trial showed that a 100 mg dose of ATRS-1902 delivered a similar pharmacokinetic profile and was both safe and well-tolerated.

Discover more about therapies set to grab major Adrenal crisis market share @ Adrenal crisis Treatment Market
https://www.delveinsight.com/report-store/adrenal-crisis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Adrenal crisis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Adrenal crisis Companies: Takeda Pharmaceutical (TSE: 4502), Sandoz International GmbH (Private), Pfizer Inc. (NYSE: PFE), Bristol-Myers Squibb (NYSE: BMY), Merck KGaA (FWB: MRK), Antares Pharma (NASDAQ: ATRS), Mallinckrodt Pharmaceutical (OTC: MNKMQ), Mylan Pharmaceutical (NASDAQ: MYL), eTon Pharmaceuticals (OTC: ETNP), and others.
• Key Adrenal crisis Therapies: ATRS-1902, and others
• Adrenal crisis Therapeutic Assessment: Adrenal crisis current marketed and Adrenal crisis emerging therapies
• Adrenal crisis Market Dynamics: Adrenal crisis market drivers and Adrenal crisis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Adrenal crisis Unmet Needs, KOL's views, Analyst's views, Adrenal crisis Market Access and Reimbursement

To know more about Adrenal crisis companies working in the treatment market, visit @ Adrenal crisis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/report-store/adrenal-crisis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.